BioNews, the Progress Educational Trust’s news service, reported on 27 July 2026 that researchers had identified HELB, a gene linked to early ovarian decline. The finding matters because ovarian decline drives when perimenopause begins, how quickly fertility falls and whether menopause arrives well before the usual age range of 45 to 55.
The NHS defines early menopause as periods stopping before 45 and premature menopause as before 40. That is the clinical window this kind of genetics work is trying to sharpen. If a gene can help explain why some women move into ovarian decline years earlier than expected, it could eventually support earlier fertility counselling, faster referral and more timely discussion of hormone treatment for women with symptoms in their 30s or early 40s.
The clearest technical link so far came from JCI Insight, which published Genetic variants in HELB contribute to premature ovarian insufficiency and early age of natural menopause on 10 November 2025. The paper focused on one affected Chinese family and used knock-in mouse work to test the biology. That is an early research signal, not a clinical tool: one family does not make HELB a screening test, and it is not something women can order or act on as a treatment decision today.
The practical value, if the signal holds up, is in risk stratification. Women with a family history of early menopause, irregular cycles in their 30s, fertility problems or unexplained loss of ovarian function could eventually be identified earlier for specialist review. That could mean quicker ovarian reserve assessment, more informed fertility-planning decisions and earlier monitoring of bone and cardiovascular health, which matter once ovarian hormones fall.
This sits inside a wider research shift. Nature published Genetic links between ovarian ageing, cancer risk and de novo mutation rates on 11 September 2024, showing ovarian ageing is now being studied as part of broader human ageing biology. A Frontiers in Endocrinology review on 26 September 2024, Primary ovarian insufficiency: update on clinical and genetic findings, underlined how genetically complex POI remains, while the American Society for Reproductive Medicine issued an evidence-based POI guideline in 2024 and the British Menopause Society said in its 5 April 2024 consensus statement that POI consequences are tied to declining ovarian function and estrogen deficiency.
For readers, the message is straightforward: this is a promising clue about why some women hit ovarian decline early, but it is still research, not a clinical test. If periods stop before 45, or before 40 in the case of premature menopause, or if cycles change sharply alongside hot flushes, sleep disruption or fertility concerns, see your GP.